Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
57%(4 trials)

Phase Distribution

Ph phase_3
2
29%
Ph phase_2
2
29%
Ph phase_4
3
43%

Phase Distribution

0

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 43 (42.9%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_4

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

NCT00417937
completedphase_2

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

NCT00408330
completedphase_2

A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis

NCT00403949
completedphase_4

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

NCT01139047
completedphase_4

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

NCT01139008
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00417937Phase 4

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

Completed
NCT00408330Phase 2

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

Completed
NCT00403949Phase 2

A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis

Completed
NCT01139047Phase 4

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

Completed
NCT01139008Phase 4

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

Completed
NCT01493687Phase 3

Phase 3 Papulopustular Rosacea Study

Completed
NCT01494467Phase 3

Phase 3 Papulopustular Rosacea Study

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7